69 related articles for article (PubMed ID: 7664296)
1. c-Myc and cyclin D3 (CcnD3) genes are independent targets for glucocorticoid inhibition of lymphoid cell proliferation.
Rhee K; Bresnahan W; Hirai A; Hirai M; Thompson EA
Cancer Res; 1995 Sep; 55(18):4188-95. PubMed ID: 7664296
[TBL] [Abstract][Full Text] [Related]
2. Simian virus 40 large T antigen J domain and Rb-binding motif are sufficient to block apoptosis induced by growth factor withdrawal in a neural stem cell line.
Slinskey A; Barnes D; Pipas JM
J Virol; 1999 Aug; 73(8):6791-9. PubMed ID: 10400777
[TBL] [Abstract][Full Text] [Related]
3. Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis.
Rezaeian AH; Inuzuka H; Wei W
Adv Protein Chem Struct Biol; 2023; 135():179-201. PubMed ID: 37061331
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D3 activates Caspase 2, connecting cell proliferation with cell death.
Mendelsohn AR; Hamer JD; Wang ZB; Brent R
Proc Natl Acad Sci U S A; 2002 May; 99(10):6871-6. PubMed ID: 12011445
[TBL] [Abstract][Full Text] [Related]
5. High mobility group protein HMGA1 inhibits retinoblastoma protein-mediated cellular G0 arrest.
Ueda Y; Watanabe S; Tei S; Saitoh N; Kuratsu J; Nakao M
Cancer Sci; 2007 Dec; 98(12):1893-901. PubMed ID: 17877762
[TBL] [Abstract][Full Text] [Related]
6. Chromosomal and extrachromosomal instability of the cyclin D2 gene is induced by Myc overexpression.
Mai S; Hanley-Hyde J; Rainey GJ; Kuschak TI; Paul JT; Littlewood TD; Mischak H; Stevens LM; Henderson DW; Mushinski JF
Neoplasia; 1999 Aug; 1(3):241-52. PubMed ID: 10935479
[TBL] [Abstract][Full Text] [Related]
7. Synergistic combination of isogarcinol isolated from edible fruits of Garcinia multiflora and dexamethasone to overcome leukemia glucocorticoid resistance.
Liu Q; Niu ZP; Yang K; Song JR; Wei XN; Huang YB; Yuan CM; Li YM
Biomed Pharmacother; 2024 Jan; 170():115936. PubMed ID: 38039755
[TBL] [Abstract][Full Text] [Related]
8. Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation.
Screaton RA; Penn LZ; Stanners CP
J Cell Biol; 1997 May; 137(4):939-52. PubMed ID: 9151695
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle and apoptosis.
Pucci B; Kasten M; Giordano A
Neoplasia; 2000; 2(4):291-9. PubMed ID: 11005563
[TBL] [Abstract][Full Text] [Related]
10. PI3Kδ inhibition potentiates glucocorticoids in B-lymphoblastic leukemia by decreasing receptor phosphorylation and enhancing gene regulation.
Zimmerman JAO; Fang M; Pufall MA
bioRxiv; 2023 Aug; ():. PubMed ID: 36798391
[TBL] [Abstract][Full Text] [Related]
11. PI3Kδ Inhibition Potentiates Glucocorticoids in B-lymphoblastic Leukemia by Decreasing Receptor Phosphorylation and Enhancing Gene Regulation.
Zimmerman JAO; Fang M; Pufall MA
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201570
[TBL] [Abstract][Full Text] [Related]
12. Transformation of mouse T cells requires MYC and AKT activity in conjunction with inhibition of intrinsic apoptosis.
Högstrand K; Darmanin S; Forshell TP; Grandien A
Oncotarget; 2018 Apr; 9(30):21396-21410. PubMed ID: 29765548
[TBL] [Abstract][Full Text] [Related]
13. Altered pathways and targeted therapy in double hit lymphoma.
Zhuang Y; Che J; Wu M; Guo Y; Xu Y; Dong X; Yang H
J Hematol Oncol; 2022 Mar; 15(1):26. PubMed ID: 35303910
[TBL] [Abstract][Full Text] [Related]
14. Dual Mechanisms of Metabolism and Gene Expression of the CCRF-CEM Leukemia Cells under Glucocorticoid Treatment.
Lambrou GI; Karakonstantakis T; Vlahopoulos S; Zaravinos A
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072627
[TBL] [Abstract][Full Text] [Related]
15. The nucleoplasmic interactions among Lamin A/C-pRB-LAP2α-E2F1 are modulated by dexamethasone.
Ricci A; Orazi S; Biancucci F; Magnani M; Menotta M
Sci Rep; 2021 May; 11(1):10099. PubMed ID: 33980953
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
Pikman Y; Alexe G; Roti G; Conway AS; Furman A; Lee ES; Place AE; Kim S; Saran C; Modiste R; Weinstock DM; Harris M; Kung AL; Silverman LB; Stegmaier K
Clin Cancer Res; 2017 Feb; 23(4):1012-1024. PubMed ID: 28151717
[No Abstract] [Full Text] [Related]
17. Differentiation resistance through altered retinoblastoma protein function in acute lymphoblastic leukemia: in silico modeling of the deregulations in the G1/S restriction point pathway.
Ouzounoglou E; Dionysiou D; Stamatakos GS
BMC Syst Biol; 2016 Mar; 10():23. PubMed ID: 26932523
[TBL] [Abstract][Full Text] [Related]
18. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.
Wu SC; Li LS; Kopp N; Montero J; Chapuy B; Yoda A; Christie AL; Liu H; Christodoulou A; van Bodegom D; van der Zwet J; Layer JV; Tivey T; Lane AA; Ryan JA; Ng SY; DeAngelo DJ; Stone RM; Steensma D; Wadleigh M; Harris M; Mandon E; Ebel N; Andraos R; Romanet V; Dölemeyer A; Sterker D; Zender M; Rodig SJ; Murakami M; Hofmann F; Kuo F; Eck MJ; Silverman LB; Sallan SE; Letai A; Baffert F; Vangrevelinghe E; Radimerski T; Gaul C; Weinstock DM
Cancer Cell; 2015 Jul; 28(1):29-41. PubMed ID: 26175414
[TBL] [Abstract][Full Text] [Related]
19. Delivery of intracellular-acting biologics in pro-apoptotic therapies.
Li H; Nelson CE; Evans BC; Duvall CL
Curr Pharm Des; 2011; 17(3):293-319. PubMed ID: 21348831
[TBL] [Abstract][Full Text] [Related]
20. A functional and regulatory network associated with PIP expression in human breast cancer.
Debily MA; Marhomy SE; Boulanger V; Eveno E; Mariage-Samson R; Camarca A; Auffray C; Piatier-Tonneau D; Imbeaud S
PLoS One; 2009; 4(3):e4696. PubMed ID: 19262752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
